To eliminate confounding influence from age and the PML-RARA fusion gene (which has favorable prognosis and is usually treated with a chemotherapy regimen that is entirely different from other AML subtypes; refs. 64, 65), we limited clinical outcome analysis to the adult (age >16) de novo cases that were not M3. The gene discussed is PML; the disease is acute myeloid leukemia.